SAN DIEGO, Jan. 07, 2024 Singular Genomics Systems, Inc. , a company leveraging novel next-generation sequencing and multiomics technologies to empower researchers and clinicians, today.
Dosing XTX301 at 45 ug/kg once every three weeks in ongoing Phase 1 trial, nearly 100x the maximum tolerated dose of rhIL-12, with no dose-limiting toxicities observed to date Initiated patient.
Dosing XTX301 at 45 ug/kg once every three weeks (dose level 3) in ongoing Phase 1 trial, nearly 100x the maximum tolerated dose of rhIL-12, with no dose-limiting toxicities observed
First Patient Dosed and Successfully Engrafted in BEACON Phase 1/2 Trial of BEAM-101 in Patients with Severe Sickle Cell Disease; Significant Enrollment Progress Supports First Expected Clinical Data.
CAMBRIDGE, Mass., Jan. 08, 2024 Relay Therapeutics, Inc. , a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and.